NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · SMALL CAP
Atyr Pharma, Inc. ATYR
13 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$190,000
▼ 19.1% vs FY2024
EPS · FY25
$-0.80
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-107.8%
Net margin · FY25
-39009.5%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 190,000.00
Revenue, FY2025 · full 13-year series below
Revenue
Net income
The company lost 39009 cents on every revenue dollar this year.
Per share
USD -0.80
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-107.8%
Return on equity, FY2025
ROE
Operating margin-40856.3%
Net margin-39009.5%
Return on assets-78.1%
Each USD of equity lost 108 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
−55.1% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
−73.7%
−55.1%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.10B
Shares outstanding, FY2025
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 93.0M
total assets, end of FY2025
Total assetsUSD 93.0M
EquityUSD 67.5M
CashUSD 10.7M
Current ratio5.30×
Equity funds 73% of total assets.
History
13 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
Revenue $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
·
·
·
·
·
Operating income $B
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EBITDA $B
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
Income tax $B
0.0
0.0
0.0
0.0
0.0
0.0
0.0
0.0
·
−0.0
·
·
·
Net income $B
−0.1
−0.1
−0.1
−0.0
−0.0
−0.0
−0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
EPS, diluted $
−0.80
−0.86
−0.94
−1.60
−1.77
−1.77
−7.03
−16.11
−26.13
−2.44
−3.03
−29.69
−28.39
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−107.8
−79.7
−62.2
−50.2
−47.9
−61.4
−59.2
−70.5
−75.9
−65.1
−399.1
·
·
Shares out B
0.10
0.08
0.06
0.03
0.03
0.01
0.00
0.00
0.03
0.02
0.02
0.00
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
37 of 37
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed